You just read:

Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes

News provided by

Eli Lilly and Company

Nov 13, 2019, 17:07 ET